Portal de investigación
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Genesca, E
- Lazarenkov, A
- Morgades, M
- Berbis, G
- Ruiz-Xiville, N
- Gomez-Marzo, P
- Ribera, J
- Junca, J
- Gonzalez-Perez, A
- Mercadal, S
- Guardia, R
- Artola, MT
- Martinez-Lopez, J
- Zamora, L
- Barba, P
- Gil, C
- Tormo, M
- Cladera, A
- Novo, A
- Pratcorona, M
- Nomdedeu, J
- Gonzalez-Campos, J
- Almeida, M
- Batlle, M
- Vives, S
- Esteve, J
- Feliu, E
- Sole, F
- Orfao, A
- Ribera, JM
Grupos
Abstract
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (<= 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.
Datos de la publicación
- ISSN/ISSNe:
- 1756-8722, 1756-8722
- Tipo:
- Article
- Páginas:
- 96-96
- PubMed:
- 30041662
- Factor de Impacto:
- 2,960 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Journal of Hematology & Oncology BMC
Citas Recibidas en Web of Science: 27
Documentos
- No hay documentos
Filiaciones
Keywords
- T-ALL; CDKN2A/ARF; CDKN2B; Prognosis; MRD
Campos de Estudio
Cita
Genesca E,Lazarenkov A,Morgades M,Berbis G,Ruiz N,Gomez P,Ribera J,Junca J,Gonzalez A,Mercadal S,Guardia R,Artola MT,MORENO MJ,Martinez J,Zamora L,Barba P,Gil C,Tormo M,Cladera A,Novo A,Pratcorona M,Nomdedeu J,Gonzalez J,Almeida M,CERVERA J,MONTESINOS P,Batlle M,Vives S,Esteve J,Feliu E,Sole F,Orfao A,Ribera JM. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J. Hematol. Oncol. 2018. 11. (1):p. 96-96. IF:8,731. (1).